Bremelanotide Acetate
Grundinformationen
- CAS
1607799-13-2- Standard-SMILES
CC(=O)O.CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O- InChIKey
MAYUSRUHXFWITM-GBRHMYBBSA-N- Summenformel
- C52H72N14O12
- Durchschnittliche Molmasse
- 1.085,2 g/mol
- Monoisotopische Masse
- 1.084,54541379
Überblick
See also: Bremelanotide (has active moiety).
Namen und Bezeichner
- Bevorzugter Name
- Bremelanotide Acetate
- IUPAC
- (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid;acetic acid
- Englischer Name
- Bremelanotide Acetate
- Summenformel
- C52H72N14O12
- Molmasse
- 1085.23
Namen und Synonyme
Bremelanotide Acetate1607799-13-2VyleesiPV2WI7495PDTXSID801027730RefChem:58356VYLEESI (AUTOINJECTOR)DTXCID001513307Bremelanotide (Acetate)Bremelanotide acetate [USAN]PT-141PT141 acetate
Weitere Namen anzeigen
Bremelanotide, PT141, AcetateValidamine PT 141 Acetateα-MSH (PT-141)，BremelanotidePT141 acetate (Bremelanotide)Bremelanotide acetate - Bio-X ?Bremelanotide Acetate, 10 mM in DMSOBremelanotide acetate (PT-141 acetate)Peptides PT141 Acetate Bremelanotide Acetate
Vyleesi (TN)(3S,6S,9R,12S,15S,23S)-12-((1H-Imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxylic acid acetic acid(3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid;acetic acidBremelanotide acetate (USAN)Bremelanotide acetate?PT-141 AcetateN-Acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine (2-7)-lactamUNII-PV2WI7495P
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 416 Ų
- H-Brücken-Donoren
- 14
- H-Brücken-Akzeptoren
- 14
- Frei drehbare Bindungen
- 17
- Schwere Atome
- 78
- Formalladung
- 0
- Komplexität
- 1.980
Experimentelle und physikochemische Eigenschaften
Human Drugs
Breastfeeding; Lactation; Milk, Human; Peptides, Cyclic
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physikochemische Eigenschaften
- storage temp.
- -20 °C · Store at -20°C
- Löslichkeit
- 10 mg/ml; · DMF: 10 mg/ml; DMSO: 10 mg/ml; Ethanol: 10 mg/ml; PBS (pH 7.2): 5 mg/ml
- Aggregatzustand
- A solid
- Farbe
- White to off-white
- InChIKey
- MAYUSRUHXFWITM-UKGCEBKRNA-N
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Toxikologische Informationen
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Bremelanotide acetate
Ambiguous-DILI-concern
4
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Chemie und Industrie
Anwendungen
BeschreibungBremelanotide Acetate (PT-141 Acetate), a synthetic peptide analogue of α-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R for the treatment of sexual dysfunction.. In Vivo: Bremelanotide Acetate (50-200 μg/kg; s.c.; once) significantly increases proceptive solicitations in females primed with Estradiol benzoate+Progesterone or Estradiol benzoate alone in bilevel chambers.
VerwendenBremelanotide is a novel drug candidate for the treatment of male and female sexual dysfunction. Bremelanotide has shown promise in effectively treating erectile dysfunction (ED) without the cardiovascular effects found in ED drugs currently available. Bremelanotide works through a mechanism of action involving the central nervous system rather than directly on the vascular system. As a result, it may offer significant safety and efficacy benefits over currently available products.
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…